Article info
PDFBackground
Paper
How to keep high-risk studies ethical: classifying candidate solutions
- Correspondence to Professor Nir Eyal, Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, 02115 Boston, MA, USA; neyal{at}hsph.harvard.edu
Citation
How to keep high-risk studies ethical: classifying candidate solutions
Publication history
- Received February 1, 2016
- Accepted February 18, 2016
- First published June 9, 2016.
Online issue publication
January 25, 2017
Article Versions
- Previous version (9 June 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Other content recommended for you
- The benefit / risk ratio challenge in clinical research, and the case of HIV cure: an introduction
- Informed consent to HIV cure research
- Subjects ’ views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study
- Assessing risk / benefit for trials using preclinical evidence: a proposal
- Ethics and epistemology of accurate prediction in clinical research
- T-cell agonists in cancer immunotherapy
- Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach
- Intraocular pressure efficacy of glaucoma medications versus placebo in phase II compared to later phase trials
- Do we really know how many clinical trials are conducted ethically? Why research ethics committee review practices need to be strengthened and initial steps we could take to strengthen them
- Implementing post-trial access plans for HIV prevention research